Early progression rates and 5-year Kaplan-Meier freedom from treatment failure (FFTF) and overall survival (OS) rates according to treatment arm and prognostic subgroup (International Prognostic Factor Project score). HD9 trial of the German Hodgkin Lymphoma Study Group (GHSG).15
| International Prognostic Score . | COPP/ABVD . | BEACOPP Baseline . | BEACOPP Escalated . |
|---|---|---|---|
| Early progression (%) | |||
| 0–1 | 10 | 6 | 2 |
| 2–3 | 11 | 9 | 2 |
| 4–7 | 18 | 9 | 3 |
| 5-year freedom from treatment failure (%) | |||
| 0–1 | 79 | 81 | 92 |
| 2–3 | 67 | 72 | 87 |
| 4–7 | 59 | 74 | 82 |
| 5-year overall survival (%) | |||
| 0–1 | 92 | 93 | 95 |
| 2–3 | 84 | 86 | 90 |
| 4–7 | 67 | 81 | 82 |
| International Prognostic Score . | COPP/ABVD . | BEACOPP Baseline . | BEACOPP Escalated . |
|---|---|---|---|
| Early progression (%) | |||
| 0–1 | 10 | 6 | 2 |
| 2–3 | 11 | 9 | 2 |
| 4–7 | 18 | 9 | 3 |
| 5-year freedom from treatment failure (%) | |||
| 0–1 | 79 | 81 | 92 |
| 2–3 | 67 | 72 | 87 |
| 4–7 | 59 | 74 | 82 |
| 5-year overall survival (%) | |||
| 0–1 | 92 | 93 | 95 |
| 2–3 | 84 | 86 | 90 |
| 4–7 | 67 | 81 | 82 |